Oncology Times - Ot Broadcasts From The Ipad Archives
Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL
- Autor: Vários
- Narrador: Vários
- Editora: Podcast
- Duração: 0:12:16
- Mais informações
Informações:
Sinopse
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed. Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor, was designed to re-establish BTK inhibition.
